An integrative scoring system for survival prediction following umbilical cord blood transplantation in acute leukemia

Roni Shouval, Annalisa Ruggeri, Myriam Labopin, Mohamad Mohty, Guillermo Sanz, Gerard Michel, Jürgen Kuball, Patrice Chevallier, Amal Al-Seraihy, Noel Jean Milpied, Cristina Diaz De Heredia, William Arcese, Didier Blaise, Vanderson Rocha, Joshua Fein, Ron Unger, Frederic Baron, Peter Bader, Eliane Gluckman, Arnon Nagler

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Purpose: Survival of acute leukemia (AL) patients following umbilical cord blood transplantation (UCBT) is dependent on an array of individual features. Integrative models for risk assessment are lacking. We sought to develop a scoring system for prediction of overall survival (OS) and leukemia-free survival (LFS) at 2 years following UCBT in AL patients. Experimental Design: The study cohort included 3,140 pediatric and adult AL UCBT patients from the European Society of Blood and Marrow Transplantation and Eurocord registries. Patients received single or double cord blood units. The dataset was geographically split into a derivation (n = 2,362, 65%) and validation set (n = 778, 35%). Top predictors of OS were identified using the Random Survival Forest algorithm and introduced into a Cox regression model, which served for the construction of the UCBT risk score. Results: The score includes nine variables: disease status, diagnosis, cell dose, age, center experience, cytomegalovirus serostatus, degree of HLA mismatch, previous autograft, and anti-thymocyte globulin administration. Over the validation set an increasing score was associated with decreasing probabilities for 2 years OS and LFS, ranging from 70.21% [68.89–70.71, 95% confidence interval (CI)] and 64.76% (64.33–65.86, 95% CI) to 14.78% (10.91–17.41) and 18.11% (14.40–22.30), respectively. It stratified patients into six distinct risk groups. The score's discrimination (AUC) over multiple imputations of the validation set was 68.76 (68.19–69.04, range) and 65.78 (65.20–66.28) for 2 years OS and LFS, respectively. Conclusions: The UCBT score is a simple tool for risk stratification of AL patients undergoing UCBT. Widespread application of the score will require further independent validation.

Original languageEnglish
Pages (from-to)6478-6486
Number of pages9
JournalClinical Cancer Research
Volume23
Issue number21
DOIs
StatePublished - 1 Nov 2017

Bibliographical note

Publisher Copyright:
©2017 AACR.

Funding

This study was supported by The Varda and Boaz Dotan Research Center in Hemato-Oncology affiliated with the CBRC of Tel Aviv University and The Shalvi Foundation for the Support of Medical Research. J. Kuball is a consultant/advisory board member for Gadeta and reports receiving commercial research grants from Gadeta, Miltenyi, and Novartis. No potential conflicts of interest were disclosed by the other authors.

FundersFunder number
Shalvi Foundation
Novartis
Tel Aviv University
Varda and Boaz Dotan Research Center for Hemato-Oncology Research, Tel Aviv University

    Fingerprint

    Dive into the research topics of 'An integrative scoring system for survival prediction following umbilical cord blood transplantation in acute leukemia'. Together they form a unique fingerprint.

    Cite this